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Abstract
During a normal menstrual cycle, serum levels of
luteinizing hormone (LH), follicle-stimulating hor-
mone (FSH), estradiol, and progesterone can vary
widely between cycles for the same woman, as well
as between different woman. Reliable reference val-
ues based on the local population are important for
correct interpretation of laboratory results. The pur-
pose of our study was to determine detailed reference
values for these hormones throughout the menstrual
cycle using the Abbott ARCHITECT system. From 20
volunteers (age 20–36 years) with normal cycles and
no use of oral contraceptives, samples were taken
every day during their cycle. Volunteers received
three vaginal ultrasound examinations (days 10 and
13, and 1 or 2 days after ovulation) to measure follic-
ular and corpus luteum development. Hormone levels
were measured using the corresponding ARCHITECT
assay and were synchronized to the LH peak. Median,
and 5th and 95th percentile values were determined
for each day of the cycle, as well as for early follicular
(days y15 to y6), late follicular (days y5 to y1), LH
peak (day 0), early luteal (q1 to q4), mid-luteal (days
q5 to q9), and late luteal (days q10 to q14) phases
of the cycle. Based on our data, we were able to
establish detailed reference values for LH, FSH, estra-
diol, and progesterone, which should aid in the inter-
pretation of results for these reproductive hormones
in a variety of circumstances.
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Normal reproductive endocrine function involves a
wide variety of hormones controlled by a number of
intricate feedback mechanisms (1). This is particularly
true during the menstrual cycle, in which serum levels
of luteinizing hormone (LH), follicle-stimulating hor-
mone (FSH), estradiol, and progesterone follow a
cyclical pattern closely coordinated by the hypothal-
mic-pituitary-gonadal axis (1, 2). Because LH, FSH,
estradiol, and progesterone play such a central role
in female reproductive function, measurement of the
serum concentration of these hormones is important
in the diagnosis, treatment, and monitoring of many
different conditions (1). According to the Clinical and
Laboratory Standards Institute (CLSI; formerly the
National Committee for Clinical Laboratory Standard-
ization, NCCLS), ‘‘for a decision making process to
occur, reference values are needed for all tests in the
clinical laboratory’’ (3). Assay manufacturers typically
provide reference range data for their assays. Ideally,
laboratories should either verify these ranges or
determine their own reference ranges, based on the
populations they serve. However, performing detailed
reference range studies can be logistically complex,
and are beyond the capabilities of many clinical
laboratories. This is especially true for reproductive
hormones, for which serum concentrations vary sig-
nificantly throughout the menstrual cycle, as well as
from woman to woman, and collection of multiple
samples across many days is required to establish
reference values with any degree of resolution (4).
The purpose of our study was to obtain detailed ref-
erence values for LH, FSH, estradiol, and progester-
one for each day and phase of the menstrual cycle
using the Abbott ARCHITECT i2000SR analyzer.
From 20 apparently healthy female volunteers (age
range 20–36 years) with normal menstrual cycles and
no use of oral contraceptives or other medications,
serum samples were collected on every day of the
cycle. Each sample was then assayed for LH, FSH,
estradiol, and progesterone using the Abbott ARCHI-
TECT i2000SR system (Abbott Diagnostics, Abbott
Park, IL, USA). Reagent list numbers for these assays
were: LH, 6C25; FSH, 6C24; estradiol, 2K25; and pro-
gesterone, 6C26. The ARCHITECT i2000SR is a high-
throughput immunoassay analyzer that utilizes
paramagnetic microparticles and chemiluminescent
detection technology (5). Assays were performed
according to the manufacturer’s instructions. Analyt-
ical performance characteristics (e.g., imprecision,
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Table 1A Reference range data for LH and FSH by day in normal cycling women.
Days from n LH, IU/L n FSH, IU/L
LH peak
Mean Median Percentile Mean Median Percentile
5th 95th 5th 95th
y15 9 2.59 2.28 0.37 5.79 9 4.44 4.59 1.95 5.86
y14 12 3.73 3.39 1.35 6.29 12 5.99 6.45 2.79 8.15
y13 15 4.10 3.47 2.35 7.36 14 6.29 6.34 4.24 7.79
y12 17 3.85 3.59 1.52 6.61 17 6.49 6.26 4.62 7.93
y11 19 4.27 3.82 2.50 7.81 19 6.87 6.61 5.50 9.01
y10 20 4.44 3.82 2.24 8.73 20 7.07 6.88 5.40 10.25
y9 20 4.46 4.26 2.43 7.39 20 6.69 6.65 5.04 8.80
y8 20 5.11 4.96 2.76 7.52 20 6.54 6.46 4.97 9.53
y7 20 5.13 4.54 3.57 7.90 20 6.74 6.63 4.66 8.59
y6 20 4.81 4.47 3.26 7.03 20 5.93 5.65 4.41 8.10
y5 20 4.42 4.18 3.11 6.68 20 5.33 5.45 4.19 7.33
y4 20 4.63 4.58 3.29 6.89 20 4.76 4.59 3.83 6.33
y3 20 5.23 5.12 3.31 7.35 20 4.61 4.35 3.55 6.62
y2 20 7.03 7.02 4.58 9.64 20 4.33 4.32 2.95 5.71
y1 20 12.55 12.36 6.36 19.08 20 5.26 5.15 3.20 8.56
0 20 42.65 41.19 21.16 73.63 20 11.54 12.82 5.30 15.07
1 20 14.54 14.92 7.47 21.38 20 8.44 8.01 5.20 15.43
2 19 7.92 7.75 3.93 13.24 19 6.20 5.19 3.78 9.51
3 20 6.66 6.26 3.15 11.00 20 5.30 4.73 3.05 8.18
4 20 6.38 6.46 3.42 9.98 20 4.72 4.36 2.71 7.10
5 19 4.91 4.32 2.53 9.19 20 4.03 3.88 2.22 5.97
6 20 5.39 4.50 1.32 10.75 19 3.64 3.34 2.01 5.53
7 20 4.14 4.29 1.04 7.20 20 3.24 3.31 1.47 5.34
8 20 3.87 3.89 1.58 5.90 20 2.97 2.97 1.53 4.88
9 20 3.19 3.07 0.73 6.51 20 2.58 2.73 1.26 4.09
10 19 2.63 1.75 0.97 6.34 19 2.40 2.55 1.12 3.57
11 20 2.85 2.52 0.49 6.05 20 2.42 2.54 1.09 3.26
12 20 3.59 3.42 0.42 7.29 20 2.84 3.08 1.13 4.37
13 16 3.13 2.55 1.19 6.05 16 3.94 3.73 1.55 7.58
14 9 3.11 3.23 0.85 6.20 8 3.80 3.81 1.54 5.78
sensitivity, method comparison) for these assays
have previously been reported (6–9). Per the manu-
facturer, the assays are standardized accordingly: LH,
WHO 2nd IS 80/552; FSH, WHO 2nd IRP 78/549; estra-
diol, gravimetric, ID-GCMS verified; progesterone,
gravimetric, USP grade progesterone. For analysis of
serum hormone concentrations, variations in the
cycle length were normalized by defining ‘‘day 0’’
based on the peak LH value for each woman. To
ensure a normal cycle was taking place, volunteers
received three vaginal ultrasound examinations (days
10 and 13, and 1 or 2 days post-ovulation) to measure
follicular and corpus luteum development. Ovulation
occurred in all cycles used for data analysis. Owing
to the highly specialized nature of the sample set
required to perform this study, obtaining a large num-
ber of specimens from many different women repre-
senting each day of their menstrual cycle was
logistically challenging. In recommendations for the
determination of reference values, the CLSI recogniz-
es that collecting large numbers of certain sample
types may be ‘‘difficult, if not impossible’’; in such
cases, their guidance is to report ‘‘percentiles appro-
priate to the number of values obtained’’ (3). In the
present study, reference values were defined by cal-
culating the median, and 5th and 95th percentiles in
sample sets of nG19, the minimum number needed
to define these percentiles (3). For sample sets with
n-19, 5th and 95th percentile values are reported for
illustrative purposes only, and these data should be
interpreted with caution. Data were analyzed using
Microsoft Excel 2000 (Microsoft, Redmond, WA,
USA). The study protocol was reviewed and approved
by the internal institutional Review Board.
Data for normal cycling women by day of cycle,
with median, and 5th and 95th percentiles, are shown
in Table 1 and represented graphically in Figure 1.
Reference values for different phases of the menstrual
cycle are shown in Table 2. During the early follicular
phase (days y15 to y6) median, and 5th and 95th
percentile values were: LH, 3.96 (2.01 and 7.80) IU/L;
FSH, 6.42 (3.91 and 8.76) IU/L; estradiol, 149.74 (77.99
and 266.08) pmol/L; and progesterone, 0.64 (0.32 and
1.91) nmol/L. For the late follicular phase (days y 5
to y1), median, and 5th and 95th percentile values
were: LH, 5.68 (3.24 and 14.68) IU/L; FSH, 4.66 (2.97
and 6.99) IU/L; estradiol, 450.49 (195.43 and 1146.91)
pmol/L; and progesterone, 0.64 (0.32 and 1.59)
nmol/L. During the LH peak (defined as day 0), medi-
an, and 5th and 95th percentile values were: LH, 41.19
(21.16 and 73.63) IU/L; FSH, 12.82 (5.30 and 15.07)
IU/L; estradiol, 671.06 (482.00 and 1425.39) pmol/L;
and progesterone, 2.54 (1.24 and 4.13) nmol/L. For the
early luteal phase (days q1 to q4), median, and 5th
and 95th percentile values were: LH, 7.86 (3.65 and
18.03) IU/L; FSH, 5.62 (3.02 and 11.09) IU/L; estradiol,
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Table 1B Reference range data for estradiol and progesterone by day in normal cycling women.
Days from n Estradiol, pmol/L n Progesterone, nmol/L
LH peak
Mean Median Percentile Mean Median Percentile
5th 95th 5th 95th
y15 9 118.42 139.46 57.55 194.44 9 1.66 1.27 0.32 3.75
y14 12 133.01 149.00 66.06 187.67 12 1.27 1.27 0.32 2.73
y13 14 133.17 137.63 75.20 189.34 14 1.02 0.95 0.52 1.59
y12 17 125.95 128.45 79.42 200.97 17 0.82 0.64 0.32 1.65
y11 19 134.65 130.29 82.98 196.75 19 0.74 0.64 0.32 1.30
y10 20 151.33 145.15 87.60 209.56 20 0.94 0.64 0.32 2.32
y9 20 159.48 154.14 93.40 224.68 20 0.72 0.64 0.32 1.29
y8 20 170.34 162.76 112.49 220.86 20 0.67 0.48 0.32 1.61
y7 20 195.90 196.16 124.67 267.23 20 0.73 0.64 0.32 1.30
y6 20 228.20 215.06 157.66 313.36 20 0.51 0.32 0.32 1.00
y5 20 269.07 262.22 190.47 346.76 20 0.57 0.48 0.32 1.02
y4 20 343.68 363.15 186.47 490.81 19 0.59 0.64 0.32 0.95
y3 20 477.27 485.72 241.52 803.56 20 0.51 0.32 0.32 0.97
y2 20 661.19 651.06 337.35 1153.76 20 0.59 0.64 0.32 1.27
y1 20 914.84 939.34 503.85 1517.67 20 1.02 0.95 0.62 1.62
0 20 780.76 671.06 482.00 1425.39 20 2.66 2.54 1.24 4.13
1 20 320.59 312.87 159.87 514.35 20 5.02 4.93 2.21 8.95
2 19 261.32 260.57 154.62 398.38 19 12.13 12.72 4.74 18.67
3 20 338.94 322.96 208.64 495.82 20 20.84 20.51 11.34 29.05
4 20 454.07 403.52 269.80 665.99 20 29.75 30.85 11.38 45.51
5 20 499.49 450.68 292.57 703.85 20 36.08 34.03 23.72 46.46
6 19 497.07 486.64 267.07 719.72 19 36.52 35.30 22.36 48.18
7 20 531.14 551.78 291.71 695.47 20 40.32 42.45 25.98 54.17
8 20 504.39 491.23 281.91 718.20 20 39.65 37.05 25.06 60.39
9 20 499.18 503.52 279.18 764.41 20 33.76 32.44 18.25 46.65
10 19 526.68 495.45 294.48 806.70 19 34.11 32.75 17.74 55.94
11 20 350.65 340.41 210.22 640.16 20 18.24 14.47 6.74 38.21
12 20 322.24 314.52 174.82 546.15 20 16.90 13.04 3.67 41.58
13 16 229.70 170.10 101.93 497.74 16 10.73 5.25 2.15 33.15
14 8 249.28 151.20 93.97 693.54 9 9.50 4.13 1.91 33.39
Figure 1 Hormone values in daily serum samples across the menstrual cycle for normal women: (A) luteinizing hormone;
(B) follicle-stimulating hormone; (C) estradiol; and (D) progesterone. Solid lines represent median values; dotted lines rep-
resent 5th and 95th percentiles.
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Table 2 Reference values during different phases of the menstrual cycle.
Phase of Days from LH, IU/L FSH, IU/L
cycle LH peak
Median Min Max Percentile Median Min Max Percentile
5th 95th 5th 95th
Early follicular y15 to y6 3.96 0.19 10.17 2.01 7.80 6.42 1.29 10.81 3.91 8.76
Late follicular y5 to y1 5.68 2.80 22.62 3.24 14.68 4.66 2.14 9.79 2.97 6.99
LH peak 0 41.19 20.48 74.83 21.16 73.63 12.82 4.65 16.28 5.30 15.07
Early luteal q1 to q4 7.86 2.03 26.17 3.65 18.03 5.62 2.22 17.04 3.02 11.09
Mid-luteal q5 to q9 3.88 0.68 12.12 1.05 9.73 3.14 0.92 7.34 1.48 5.31
Late luteal q10 to q14 2.75 0.21 8.02 0.51 6.98 2.85 0.89 7.67 1.14 5.64
Estradiol, pmol/L Progesterone, nmol/L
Median Min Max Percentile Median Min Max Percentile
5th 95th 5th 95th
Early follicular y15 to y6 149.74 49.91 358.93 77.99 266.08 0.64 0.32 4.77 0.32 1.91
Late follicular y5 to y1 450.49 152.31 1568.93 195.43 1146.91 0.64 0.32 2.23 0.32 1.59
LH peak 0 671.06 372.87 1884.91 482.00 1425.39 2.54 0.64 4.13 1.24 4.13
Early luteal q1 to q4 313.42 101.29 1068.34 178.14 566.43 13.67 1.91 46.11 3.15 39.65
Mid-luteal q5 to q9 495.82 252.13 1163.02 275.95 761.67 36.25 14.63 71.87 21.21 54.28
Late luteal q10 to q14 327.36 51.75 962.27 100.52 787.14 13.99 0.95 69.96 1.96 49.18
313.42 (178.14 and 566.43) pmol/L; and progesterone,
13.67 (3.15 and 39.65) nmol/L. During the mid-luteal
phase (days q5 to q9), median, and 5th and 95th per-
centile values were: LH, 3.88 (1.05 and 9.73) IU/L; FSH,
3.14 (1.48 and 5.31) IU/L; estradiol, 495.82 (275.95 and
761.67) pmol/L; and progesterone, 36.25 (21.21 and
54.28) nmol/L. For the late-luteal phase (days q10 to
q14), median, and 5th and 95th percentile values
were: LH, 2.75 (0.51 and 6.98) IU/L; FSH, 2.85 (1.14 and
5.64) IU/L; estradiol, 327.36 (100.52 and 787.14)
pmol/L; and progesterone, 13.99 (1.96 and 49.18)
nmol/L.
In general, our data are in agreement with those
provided by the assay manufacturer. However, direct
comparison is difficult, as our data were analyzed to
a higher degree of resolution, allowing establishment
of reference values in greater detail throughout the
menstrual cycle. It should be noted that gonadotropin
hormones are known to be highly heterogeneous (10,
11). This heterogeneity is presumably one of the fac-
tors that leads to assay differences reported in the
literature (12). These differences can, in turn, affect
interpretation of results from different assay manu-
facturers or laboratories. For example, FSH concen-
tration on day 3 of the menstrual cycle (along with
estradiol and inhibin B) is commonly used by physi-
cians to evaluate ovarian reserve. Taieb and col-
leagues, in their study of six different immunoassays
for FSH, noted statistically significant differences for
day-3 FSH values, depending on which immunoassay
was used. Their data prompted them to recommend
‘‘that it is advisable to refer patients to selected lab-
oratories using analytical methods for which they
have defined reference values «’’ (12). Similarly,
measurement of serum estradiol is important in eval-
uating a variety of conditions, including abnormal
menstrual cycles. However, measurement of steroid
hormones (such as estradiol) by immunoassay is
notoriously difficult, and differences in assay perform-
ance significant enough to affect clinical utility have
been reported (6). For these reasons, it is especially
important for physicians and laboratories to be aware
of the potential sources of differences that exist
between immunoassay methodologies, and confirm
that the reference values they use for reproductive
hormones are valid for the populations they serve.
Based on our study, we were able to develop detailed
reference ranges for LH, FSH, estradiol, and proges-
terone on the Abbott ARCHITECT analyzer during the
normal menstrual cycle. These data should aid labo-
ratories and physicians in the interpretation of results
for these reproductive hormones in a wide variety of
clinical settings.
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